



Editor

Tore K Kvien

Associate Editors

Francis Berenbaum
Hans Bijlsma
David Pisetsky
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 7383 6250
F: +44 (0)20 7383 6668
E: ard@bmj.com
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 9.111

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2014 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Techset and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.



Receive regular table of contents by email.
Register using this QR code.

Editorial

- 791** Bariatric surgery as urate-lowering therapy in severe obesity
H K Choi, Y Zhang

Viewpoint

- 794** The emerging problem of biological treatment in migrant and travelling populations: it is time to extend guidelines for the screening of infectious diseases
F Bartalesi, A Bartoloni, Z Bisioffi, M Spinicci, F G Sánchez, J Muñoz, P Richi, G Minisola, S Muñoz-Fernandez, M Mautucci-Cerinic

Clinical and epidemiological research

- 797** Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study
N Dalbeth, P Chen, M White, G D Gamble, C Barratt-Boyes, P J Gow, B Orr-Walker

- 803** Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study
M Dougados, K Kissel, P G Conaghan, E M Mola, G Schett, R Gerli, M S Hansen, H Amital, R M Xavier, O Troum, C Bernasconi, T W J Huizinga

- 810** The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy
P G Conaghan, C Peterfy, E Olech, J Kaine, D Ridley, J DiCarlo, J Friedman, J Devenport, O Troum

- 817** Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)
D Poddubnyy, K-G A Hermann, J Callhoff, J Listing, J Sieper

- 824** Effect of bisphosphonate use in patients with symptomatic and radiographic knee osteoarthritis: data from the Osteoarthritis Initiative
L L Laslett, S R Kingsbury, E M A Hensor, M A Bowes, P G Conaghan

- 831** Peg-IFN α /ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24
D Saadoun, M R Rigon, V Thibault, M Longuet, S Pol, F Blanc, G Pialoux, A Karas, D Bazin-Karra, C Cazorla, D Vittecoq, L Musset, O Decaux, J M Ziza, O Lambotte, P Cacoub

- 838** Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials
V Strand, R A Levy, R Cervera, M A Petri, H Birch, W W Freimuth, Z J Zhong, A E Clarke, for the BLISS-52 and -76 Study Groups

- 845** Predictors of work disability during the first 3 years after diagnosis in a national rheumatoid arthritis inception cohort
T Olofsson, I F Petersson, J K Eriksson, M Englund, J F Simard, J-Å Nilsson, P Geborek, L T H Jacobsson, J Asklings, M Neovius

- 854** Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies
A Kleyer, S Finzel, J Rech, B Manger, M Krieter, F Faustini, E Araujo, A J Hueber, U Harre, K Engelke, G Schett

- 861** What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review
J A B van Nies, A Krabben, J W Schoones, T W J Huizinga, M Kloppenburg, A H M van der Helm-van Mil

- 871** Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis
E Salgado, J R Maneiro, L Carmona, J J Gomez-Reino

- 883** The relationship between longitudinal serum leptin measures and measures of magnetic resonance imaging-assessed knee joint damage in a population of mid-life women
C A Karvonen-Gutierrez, S D Harlow, J Jacobson, P Mancuso, Y Jiang

- 890** Genetics of toll like receptor 9 in ANCA associated vasculitides
C A Husmann, J U Holle, F Moosig, S Mueller, B Wilde, J W C Tervaert, L Harper, G Assmann, W L Gross, J T Epplen, S Wiczorek

- 897** FMF50: a score for assessing outcome in familial Mediterranean fever
S Ozen, E Demirkaya, A Duzova, O Erdogan, E Erken, A Gul, O Kasapcopur, T Kasifoglu, B Kisacik, H Ozdogan, M Tunca, C Acikel, for the FMF Arthritis Vasculitis and Orphan disease Research in pediatric rheumatology (FAVOR) and Turkish FMF study group

- 902** Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net project
M A Stoffer, J S Smolen, A Woolf, A Ambrozic, A Bosworth, L Carmona, V Fialka-Moser, E Loza, P Olejnik, I F Petersson, T Uhlig, T A Stamm, the eumusc.net-working group

- 906** Development of healthcare quality indicators for rheumatoid arthritis in Europe: the eumusc.net project
I F Petersson, B Strömbeck, L Andersen, M Cimmino, R Greiff, E Loza, C Sciré, T Stamm, M Stoffer, T Uhlig, A D Woolf, T P M V Vlieland, the eumusc.net-working group

MORE CONTENTS ►



This article has been chosen by the Editor to be of special interest or importance and is freely available online.



This article has been made freely available online under the BMJ Journals Open Access scheme.
See <http://ard.bmj.com/site/about/guidelines.xhtml#open>



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

- 909** Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy
S Das, E M Vial, S Horton, D Bryer, Y El-Sherbiny, A C Rawstron, F Ponchel, P Emery, M H Buch

Basic and translational research

- 913** Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up
M Zong, C Dorph, M Dastmalchi, H Alexanderson, J Pieper, P Amoudruz, S B Helmers, I Nennesmo, V Malmström, I E Lundberg
- 921** Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden. CETP mice—a translational model for atherosclerosis
L M Gierman, S Kühnast, A Koudijs, E J Pieterman, M Kloppenburg, G J V M van Osch, V Stojanovic-Susulic, T W J Huizinga, H M G Princen, A-M Zuurmond
- 928** Hypoxia and hypoxia-inducible factor-1 α provoke toll-like receptor signalling-induced inflammation in rheumatoid arthritis
F Hu, R Mu, J Zhu, L Shi, Y Li, X Liu, W Shao, G Li, M Li, Y Su, P L Cohen, X Qiu, Z Li

Letters

- 937** Testing the role of vitamin D in response to antitumour necrosis factor α therapy in a UK cohort: a Mendelian randomisation approach
A Yarwood, S Viatte, D Plant, A W Morgan, J Isaacs, A G Wilson, K Hyrich, S Eyre, A Barton, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS)
- 939** Fibrosis biomarkers in isolated Raynaud's phenomenon: too little, too soon?
F Ingegnoli, R Gualtierotti, T Schioppo, A Orenti, P Boracchi, C Lubatti, C Mastaglio, V Galbiati, A Murgo, S Zeni, C Grossi, O Borghi, W Rosenberg, L Castelnovo, L M Pier
- 940** Antitumour necrosis factor α treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients
F Genre, R López-Mejías, J A Miranda-Filloo, B Ubilla, B Camero-López, I Gómez-Acebo, R Blanco, R Ochoa, J Rueda-Gotor, T Pina, C González-Juanatey, J Llorca, M A González-Gay
- 942** Use of statins is associated with a lower prevalence of generalised osteoarthritis
A M Valdes, W Zhang, K Muir, R A Maciewicz, S Doherty, M Doherty



OPEN ACCESS

- 944** Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy
N Nishina, J Kikuchi, M Hashizume, K Yoshimoto, H Kameda, T Takeuchi
- 946** Efficacy of intra-articular bevacizumab for relapsing diffuse-type giant cell tumour
M J Nissen, A Boucher, L Brulhart, J Menetrey, C Gabay

Miscellaneous

- 948** Retraction

Electronic pages

- e25** When is it not ethical to withhold treatment for rheumatoid arthritis?
Y Yazici
- e26** Response to: 'When is it not ethical to withhold treatment for rheumatoid arthritis?' by Dr Yusuf Yazici
T Takeuchi
- e27** The influence of inflammation in the development of subclinical atherosclerosis in psoriatic arthritis: comment on 'Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review' by Jamnitski *et al*
M A González-Gay, C González-Juanatey, J Llorca, S Castañeda
- e28** Response to: 'The influence of inflammation in the development of subclinical atherosclerosis in psoriatic arthritis' by González-Gay *et al*
M T Nurmohamed, A Jamnitski, D Symmons, M J L Peters, N Sattar, I McInnes
- e29** Are autoantibodies to RNA-polymerase III to be incorporated in routine diagnostic laboratory algorithms for systemic autoimmune rheumatic diseases?
J Damoiseaux
- e30** Response to: 'Are autoantibodies to RNA-polymerase III to be incorporated in routine diagnostic laboratory algorithms for systemic autoimmune rheumatic diseases?' by Jan Damoiseaux
J Fransen, J Pope, M Baron, S Johnson, D Khanna, M Matucci-Cerinic, A Tyndall, F van den Hoogen